Skip to content

Clinical observation of remimazolam combined with remifentanil for sedation and analgesia in large area liposuction

Clinical observation of remimazolam combined with dexmedetomidine and remifentanil for sedation and analgesia in large-area liposuction

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062292
Enrollment
Unknown
Registered
2022-07-31
Start date
2022-08-25
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fat accumulation

Interventions

remimazolam combined with dexmedetomidine and remifentanil group :Remimazolam, dexmedetomidine and remifentanil
Dexmedetomidine and remifentanil group:Dexmedetomidine and remifentanil

Sponsors

Department of Anesthesiology, Plastic Surgery Hospital of Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Perform large-area liposuction involving intraoperative position changes; 2) Complete medical history, physical signs, auxiliary examination, and other clinical medical records; 3) Age 18-60, regardless of gender; 4) BMI >18; 5) Understand and voluntarily participate in the study and sign the informed consent; 6) Have an ASA grade of I.

Exclusion criteria

Exclusion criteria: 1. Allergic history of benzodiazepines and dexmedetomidine; 2. Injection site infection; 3. Mental or nervous system problems, communication disorders and inability to cooperate; 4. History of drug abuse and alcoholism; 5. Pregnant or lactating patients; 6. Intraoperative vital signs are difficult to maintain normal, or severe complications occur and need to be transferred to ICU; 7. Participated in drug clinical trials as a subject within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Patient satisfaction and surgeon satisfaction scores;

Secondary

MeasureTime frame
Duration of patient awakening;The occurrence of adverse reactions;Drug-induced dosage and total dosage;Complementary medication;The duration of induction;Vital signs (heart rate, blood pressure, respiratory rate, BIS value);Sedative effect score;Duration of position change;

Countries

China

Contacts

Public ContactWei Lingxin

Plastic Surgery Hospital of Chinese Academy of Medical Sciences

weilx3934@sina.com+86 136 2115 9500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026